T. Rowe Price Associates

Rounds

• A AdvanCellDevelops targeted alpha therapies for cancer and expands clinical and commercial manufacturing capacity. $315MSeries D · 15 Jul
• I iCapitalLeadPlatform giving wealth managers access to private-market and alternative investments. $820MGrowth · 10 Jul

No round matches these filters.

Often invests with

• Abingworth1
• Ally Bridge Group1
• Alpha Wave1
• Bain Capital Life Sciences1
• BNY1
• Eli Lilly and Company1
• Eventide Asset Management1
• Fidelity Management & Research Company1